Sale!

Semaglutide (Genetical Recombination) Tablets 3mg (Rybelsus® / リベルサス錠3mg)

元の価格は JPY ¥18,600 でした。現在の価格は JPY ¥16,368 です。

Japanese Type 2 Diabetes Treatment Agent, Oral GLP-1 Receptor Agonist (Semaglutide (Genetical Recombination) 3mg). Oral tablet for once-daily administration in type 2 diabetes mellitus. 100 tablets [10 tablets (PTP) x 10]. Mfd. by Novo Nordisk Pharma Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥17,112
10 - 19 12% JPY ¥16,368
20 + 18% JPY ¥15,252
SKU: RYB-3-TAB Category:

Description

Product Overview / 商品概要

Rybelsus Tablets 3mg (リベルサス錠3mg)
Generic: Semaglutide (Genetical Recombination) / セマグルチド(遺伝子組換え)
Therapeutic Category: Type 2 Diabetes Treatment Agent, Oral GLP-1 Receptor Agonist / 2型糖尿病治療剤 経口GLP-1受容体作動薬
Manufactured by: Novo Nordisk Pharma Ltd. / ノボ ノルディスク ファーマ株式会社

Composition & Specification / 組成・規格

Active Ingredient: Semaglutide (Genetical Recombination) 3mg per tablet / 1錠中セマグルチド(遺伝子組換え)3mg
Additives: Sodium salcaprozate, Povidone, Microcrystalline cellulose, Magnesium stearate / サルカプロザートナトリウム、ポビドン、結晶セルロース、ステアリン酸マグネシウム
Appearance: White to pale yellow oval tablet; major axis: 13.5mm, minor axis: 7.5mm, thickness: 6mm, weight: 400.7mg, identification code: 3 novo
外観: 白色~淡黄色の錠剤(楕円形)、長径:13.5mm、短径:7.5mm、厚さ:6mm、重量:400.7mg、識別コード:3 novo

Indications / 効能効果

EN: Type 2 Diabetes Mellitus
JA: 2型糖尿病

Dosage and Administration / 用法用量

EN: In adults, the maintenance dose is 7mg once daily orally as semaglutide (genetical recombination). Treatment should be initiated at 3mg once daily, and after at least 4 weeks, increased to 7mg once daily. The dose may be adjusted based on the patient’s condition; if 7mg once daily is insufficient after at least 4 weeks, the dose may be increased to 14mg once daily.
JA: 通常、成人には、セマグルチド(遺伝子組換え)として1日1回7mgを維持用量とし経口投与する。ただし、1日1回3mgから開始し、4週間以上投与した後、1日1回7mgに増量する。なお、患者の状態に応じて適宜増減するが、1日1回7mgを4週間以上投与しても効果不十分な場合には、1日1回14mgに増量することができる。

Contraindications / 禁忌

EN: 1. Patients with a history of hypersensitivity to any component of this product. 2. Patients with diabetic ketoacidosis, diabetic coma or pre-coma, or type 1 diabetes. 3. Emergency situations such as severe infections or surgery.
JA: 1. 本剤の成分に対し過敏症の既往歴のある患者 2. 糖尿病性ケトアシドーシス、糖尿病性昏睡又は前昏睡、1型糖尿病の患者 3. 重症感染症、手術等の緊急の場合

Regulatory Information / 規制情報

Approval No.: 30200AMX00513000
Sales Started: February 2021 / 2021年2月
Classification Code: 872499
Storage: Store at room temperature / 室温保存
Shelf Life: 36 months / 36ヵ月

Packaging / 包装

Main Package (for sale): 100 tablets [10 tablets (PTP) x 10] / 100錠[10錠(PTP)×10]
Other Available Packages (by special order): 100 tablets [10 tablets (PTP) x 10]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Semaglutide (Genetical Recombination) Tablets 3mg (Rybelsus® / リベルサス錠3mg)”

メールアドレスが公開されることはありません。 が付いている欄は必須項目です

Export from Japan — Semaglutide (Genetical Recombination) Tablets 3mg (Rybelsus®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.